These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27387241)

  • 1. Determination of advanced glycation end-products and antibodies against them (anti-CML and anti-CEL) in the serum of Graves' orbitopathy patients before and after methylprednisolone treatment.
    Strzelczyk J; Szumska M; Damasiewicz-Bodzek A; Krywult A; Długaszek M; Czubilińska J; Gawlik K; Synowiec K; Tyrpień-Golder K; Poczkaj K; Kos-Kudła B
    Endokrynol Pol; 2016; 67(4):383-9. PubMed ID: 27387241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of anti-advanced glycation end product antibodies to nonenzymatically lysine-derived and arginine-derived glycated products.
    Choi YG; Lim S
    J Immunoassay Immunochem; 2009; 30(4):386-99. PubMed ID: 19739013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional antibody against Nepsilon-(carboxymethyl)lysine (CML) shows cross-reaction to Nepsilon-(carboxyethyl)lysine (CEL): immunochemical quantification of CML with a specific antibody.
    Koito W; Araki T; Horiuchi S; Nagai R
    J Biochem; 2004 Dec; 136(6):831-7. PubMed ID: 15671494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
    Engelen L; Persson F; Ferreira I; Rossing P; Hovind P; Teerlink T; Stehouwer CD; Parving HH; Schalkwijk CG
    Nephrol Dial Transplant; 2011 Nov; 26(11):3573-7. PubMed ID: 21385863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An autoantibody against N(ε)-(carboxyethyl)lysine (CEL): possible involvement in the removal of CEL-modified proteins by macrophages.
    Mera K; Nagai R; Takeo K; Izumi M; Maruyama T; Otagiri M
    Biochem Biophys Res Commun; 2011 Apr; 407(2):420-5. PubMed ID: 21402053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentration of VEGF and PDGF-AA in patients with active thyroid orbitopathy before and after immunosuppressive therapy.
    Nowak M; Marek B; Karpe J; Kos-Kudla B; Sieminska L; Kajdaniuk D; Treszer M
    Exp Clin Endocrinol Diabetes; 2014 Nov; 122(10):582-6. PubMed ID: 25140996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
    Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.
    Vannucchi G; Covelli D; Currò N; Dazzi D; Maffini A; Campi I; Bonara P; Guastella C; Pignataro L; Ratiglia R; Beck-Peccoz P; Salvi M
    J Clin Endocrinol Metab; 2012 May; 97(5):E755-9. PubMed ID: 22399512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutaraldehyde is an effective cross-linker for production of antibodies against advanced glycation end-products.
    Mera K; Nagai M; Brock JW; Fujiwara Y; Murata T; Maruyama T; Baynes JW; Otagiri M; Nagai R
    J Immunol Methods; 2008 May; 334(1-2):82-90. PubMed ID: 18353354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum interleukin-16 and RANTES during treatment of Graves' orbitopathy with corticosteroids and teleradiotherapy.
    Mysliwiec J; Palyga I; Nikolajuk A; Kowalska A; Gorska M
    Endokrynol Pol; 2012; 63(2):92-6. PubMed ID: 22538746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
    van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
    Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The blood concentration of intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) in patients with active thyroid-associated orbitopathy before and after methylprednisolone treatment.
    Nowak M; Wielkoszyński T; Kos-Kudła B; Marek B; Karpe J; Kajdaniuk D; Siemińska L; Głogowska-Szelag J; Foltyn W; Strzelczyk J; Nowak K
    Endokrynol Pol; 2007; 58(6):487-91. PubMed ID: 18205104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of immunosuppressive treatment of Graves' orbitopathy is not affected by previous anti-thyroid drugs or by radioiodine therapy of Graves' disease.
    Jagiełło-Korzeniowska A; Sokołowski A; Krzentowska-Korek A; Miklaszewska G; Bałdys-Waligórska A
    Endokrynol Pol; 2016; 67(6):554-561. PubMed ID: 28042648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII.
    Miśkiewicz P; Milczarek-Banach J; Rutkowska-Hinc B; Kondracka A; Bednarczuk T
    J Endocrinol Invest; 2019 Feb; 42(2):217-225. PubMed ID: 29949121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced protein glycation in psoriasis.
    Damasiewicz-Bodzek A; Wielkoszyński T
    J Eur Acad Dermatol Venereol; 2012 Feb; 26(2):172-9. PubMed ID: 21395695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pulse methylprednisolone and oral methylprednisolone treatments on serum levels of oxidative stress markers in Graves' ophthalmopathy.
    Akarsu E; Buyukhatipoglu H; Aktaran S; Kurtul N
    Clin Endocrinol (Oxf); 2011 Jan; 74(1):118-24. PubMed ID: 21044110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunochemical detection of Nepsilon-(carboxyethyl)lysine using a specific antibody.
    Nagai R; Fujiwara Y; Mera K; Yamagata K; Sakashita N; Takeya M
    J Immunol Methods; 2008 Mar; 332(1-2):112-20. PubMed ID: 18242632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients.
    Vay D; Vidali M; Allochis G; Cusaro C; Rolla R; Mottaran E; Bellomo G; Albano E
    Diabetologia; 2000 Nov; 43(11):1385-8. PubMed ID: 11126407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous Determination of N
    Gong RZ; Wang YH; Wang YF; Chen B; Gao K; Sun YS
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30558131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.